Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA
Jonathan S. Berek(Stanford Health Care), Neville F. Hacker(New South Wales Department of Health), Candace Howe(University of California, Los Angeles), Leo D. Lagasse(University of California, Los Angeles)
Cited by 264
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Revised FIGO staging for carcinoma of the cervix uteri
|International Journal of Gynecology & Obstetrics|2019|1k